Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

LONDON -- Britain's new Labour Party government announced billions of dollars in investment in U.K. artificial intelligence, ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

The Lilly Ledbetter Fair Play Act plugged a loophole that foiled her wage discrimination claims against Goodyear and its ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.